Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.750 +0.100 (+2.74%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	2,813,414
Open	3.650
Bid (Size)	3.690 (200)
Ask (Size)	3.790 (500)
Prev. Close	3.650
Today's Range	3.520 - 3.815
52wk Range	1.660 - 4.537
Shares Outstanding	81,632,619
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗

May 31, 2026

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Via The Motley Fool

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

May 28, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Performance

YTD	+82.9%	+82.9%
1 Month	+41.8%	+41.8%
3 Month	+37.9%	+37.9%
6 Month	+88.4%	+88.4%
1 Year	+47.6%	+47.6%

More News

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Tuesday? ↗

May 26, 2026

Via Chartmill

Editas Medicine Announces Proposed Public Offering

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

May 26, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

May 14, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces First Quarter 2026 Results and Business Updates

May 05, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

April 27, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

March 27, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Is Editas Medicine Going to $0? ↗

March 17, 2026

Via The Motley Fool

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

March 09, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

February 23, 2026

From Editas Medicine, Inc.

Via GlobeNewswire

Editas (EDIT) Q2 2024 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗

November 10, 2025

Via Chartmill

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

November 10, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

Via TokenRing AI

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

November 03, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Via Benzinga

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

October 09, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗

October 07, 2025

Via Chartmill

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

October 06, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Via Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

September 05, 2025

Via Benzinga

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

September 02, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?

Yes, Editas Medicine, Inc. - Common Stock is publicly traded.

What exchange does Editas Medicine, Inc. - Common Stock trade on?

Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Editas Medicine, Inc. - Common Stock?

The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market

What is the current price of Editas Medicine, Inc. - Common Stock?

The current price of Editas Medicine, Inc. - Common Stock is 3.750

When was Editas Medicine, Inc. - Common Stock last traded?

The last trade of Editas Medicine, Inc. - Common Stock was at 07/07/26 04:00 PM ET

What is the market capitalization of Editas Medicine, Inc. - Common Stock?

The market capitalization of Editas Medicine, Inc. - Common Stock is 306.12M

How many shares of Editas Medicine, Inc. - Common Stock are outstanding?

Editas Medicine, Inc. - Common Stock has 306M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.